PIKA Rabies Vaccine

Rabies infection is highly dangerous, with a 100 percent mortality rate if treatment is not administered quickly following exposure. Exposure to potential infection, often from a dog bite, is a significant risk. In China, 12 to 14 million people each year receive preventive treatment following exposure. Current post-exposure rabies vaccines require multiple injections over a period of up to 28 days. These vaccines provide poor protection for individuals with weak or compromised immunity, including children and those over the age of 65.

An ideal rabies vaccine that could elicit a more robust immune response could provide immune protection in a shorter time, providing improved protection especially in populations without access to effective treatment. The PIKA Rabies Vaccine consists of purified inactivated rabies virus coupled with PIKA immunomodulating agent. Because of the high level and rapid onset of protective immune responses, the PIKA Rabies Vaccine is designed to allow a three-visit, one-week treatment regimen, providing accelerated protection against rabies infection. This product has been cited as a novel vaccine by the World Health Organization, and classified as a therapeutic biologics product by the China National Medical Products Administration.


Preventive Hepatitis B Vaccine with a Short Duration Regimen

Hepatitis B infection is a major health concern worldwide, particularly in Asia and Africa. The World Health Organization estimates that 600,000 people die each year due to consequences of chronic hepatitis B infection such as cirrhosis and liver cancer, and approximately 40,000 die each year from the effects of acute infection. Current vaccines do not provide adequate protection to defined at-risk populations and require a three-dose regimen that limits broad accessibility.

The YS-HBV-001 is designed with PIKA technology as a new generation of hepatitis B vaccine with two doses over one month to replace the existing 3 doses over 6 months of conventional vaccines. Early stage clinical studies have demonstrated comparable immune response of YS-HBV-001 delivered in three doses over one month as compared with the standard vaccine in a three-dose, six month regimen. YS-HBV-001 also demonstrated its capability of stimulating higher levels of antibody production as well as more robust and lasting T cell response.


Biotherapeutic for Chronic Hepatitis B

Although there are an estimated 257 million individuals worldwide living with chronic hepatitis B infection, current therapeutics have a low rate of reducing viral production to levels considered to be a functional cure. In order to provide an effective cure for hepatitis B, immune-based intervention to improve T cell activity will play an essential role. PIKA has been demonstrated in humans to elicit robust production of antigen specific multi-functional T cells. YS-HBV-002 is developed as a multiple component biologics to treat chronic hepatitis B infection.

Preclinical Immunological Programs

Yisheng is also developing multiple immunological products based on PIKA technology to confer high levels of protection against infectious disease. Vaccines against influenza, herpes zoster, rotavirus, Haemophilus b and diphtheria are currently in preclinical development.